Felix Korell
@FpkMd
M.D., Research Fellow @MassGeneral @MarcelaMaus Lab. Focus: cellular immunotherapy, precision medicine, alloSCT @uniklinik_hd & @Schmitt_lab Tweets are my own
Check out this must-read commentary from my good friend @EliDarnellMD and my mentor @MarcelaMaus on a study investigating the impact of TME on CART efficacy within the ZUMA7 trial doi.org/10.1016/j.xcrm… @MGHCancerCenter #WeekendReading
Must-read editorial on the amazing CARv3-TEAM-E study @MGHCancerCenter for glioblastoma led by @BryanDChoi & @MarcelaMaus, based on translational work from our Lab #CARTcells @OncoAlert
Science behind the Study: CAR T-Cell Therapy for Glioblastoma nej.md/49yGoKf #Neurology
aacrjournals.org/clincancerres/… "Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma" I am delighted to have contributed to this outstanding work! A heartfelt congratulations to Marc Werli!
Hot off the press! Our work on second primary malignancies after commercial CAR T cells is out today in Blood. The FDA released scant information regarding the cases of T cell malignancies after CAR T therapy. Here, we provide more context by diving deep into the FDA Adverse…
Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at the Mass General Cancer Center with @MarcelaMaus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6014Wf0K @NEJM
Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at the Mass General Cancer Center with @MarcelaMaus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6017Wf5Z @NEJM
A novel CAR T-cell therapy directed at EGFRvIII with a secretable EGFR T-cell engager produced rapid responses in three patients with recurrent glioblastoma, but the responses were transient in two of the three. Read the Brief Report for the full study: nej.md/3VnjUIq
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter! nej.md/3VnjUIq
Potential gamechanger! Huge congrats to @BryanDChoi @MarcelaMaus & team! @MGHCancerCenter
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter! nej.md/3VnjUIq
nejm.org/doi/full/10.10… Amazing findings coming out of the Maus lab! Great step forward to GBM treatment. Congrats to all the authors on their incredible work.
#CARTcell all-star @MarcelaMaus shares her latest in novel CAR targets & limiting irAEs at #AACRbcd24. Highlighting need to harmonize single-cell correlative analyses OUT NOW as InFocus in @BCD_AACR w/ @njharlen: aacrjournals.org/bloodcancerdis… 1/2
Amazing to have this out now @eClinicalMed: our work on cardiotoxicity after CAR T cell therapy & utilizing biomarkers such as hs-cTnT. Thanks for the great collaboration between @Kardioonkologie - led by @LorenzLehmann &team - and @med5_ukhd! @uniklinik_hd #CARTcells
Happy to share our last collaborative work! Great job by @FpkMd and all co-workers! Cardiovascular side effects and predictive value of cardiac biomarker (e.g., hs-cTnT)in patients treated with CAR T cell therapies @uniklinik_hd @Kardioonkologie @AG40_DGK sciencedirect.com/science/articl…
Preclinical study in @CCR_AACR on a next generation mesothelin targeted CAR T cell modality in #PancreaticCancer Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma Collaboration between @MGHCancerCenter &…
Thrilled to launch my lab @Uniklinikum_Wue & @Uni_WUE with @dfg_public Emmy Noether & @Myeloma_Society support. So grateful to @JKeithJoung, Vikram Pattanayak, @H_Einsele & Michael Hudecek. We develop new treatments for cancer patients using #CRISPR 2.0 & CAR-T technology.
AML is an evasive, multi-arm(ed) foe that needs to be disarmed by continuous translational research efforts to increase treatment for our patients. Here we review recent results and highlight future directions. febs.onlinelibrary.wiley.com/doi/10.1002/18… @hi_stem_lab @amleppa @AlexWaclawiczek
We are excited to announce the first of three Breakthrough Award recipients. Congratulations Max Jan, MD, PhD, Robert Manguso, PhD, Marcela Maus, MD, PhD, and Debattama Sen, PhD! The team is working to optimize CAR T-cell immunotherapy. Learn more: spklr.io/6011Ww7f
Low risk of second tumor after CAR T-cell immunotherapy! Our research will reassure the scientific community, healthcare providers, and patients about the unmet positive outcomes of CAR T-cell immunotherapy! Fresh off the press @RuellaLab @PennMDForum @MarcoRuella
Profiling a case of secondary T cell lymphoma following anti-CD19 #CARTcells suggests this was not caused by CAR insertional mutagenesis, with analysis indicating low secondary TCL risk after treatment @guido_ghilardi @MarcoRuella @RuellaLab @PennMedicine nature.com/articles/s4159…
2023: The rise of precision cellular therapies. In this Year in Review, I highlight 3 major advances set to transform the treatment of autoimmune and rheumatic diseases. From CAR-T cells to antigen-specific, precision immunotherapies. Link: rdcu.be/dvsaG
Venetoclax in myeloma: to B, or not to B | Blood | American Society of Hematology. Editorial by @RaabMarc on the role of t(11;14) plasma cell epigenetic & transcriptional plasticity in venetoclax resistance published by Paola Neri & @NoemieLeblay ashpublications.org/blood/article/…
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL loom.ly/KqGp-cI #researchletter #immunobiologyandimmunotherapy